Preclinical studies demonstrate that in a KRAS G12D-mutant AsPC-1 human pancreatic cancer xenograft model (nude mice), intravenous administration of HRS-4642 significantly inhibits tumor growth in a dose-dependent manner with favorable tolerability (Zhou et al., 2024). Here, KRAS is linked to neoplasm.